Gaba A Receptor Alpha 1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
GABA-A α1 is a subunit of the GABA-A receptor, the major inhibitory neurotransmitter receptor in the central nervous system. The GABA-A α1 subunit (encoded by the GABRA1 gene) is the most abundantly expressed α subunit in the brain and forms part of the majority of synaptic GABA-A receptors.
| Property |
Value |
| Protein Name |
GABA-A Receptor Alpha 1 |
| Gene |
GABRA1 |
| UniProt ID |
P14867 |
| Molecular Weight |
~51 kDa |
| Structure |
Ligand-gated chloride channel (pentameric) |
| Subcellular Localization |
Plasma membrane, synapses |
| Brain Expression |
Highest in cortex, hippocampus, thalamus |
GABA-A receptors are pentameric ligand-gated chloride channels composed of 19 subunits (α1-6, β1-3, γ1-3, δ, ε, θ, π, ρ1-3):
- Subunit composition: Typically 2 α subunits, 2 β subunits, and 1 γ/δ subunit
- α1-containing receptors: Most abundant (~60% of all GABA-A receptors)
- Benzodiazepine binding site: Located at the α1/γ2 interface
- Alternative splicing: Multiple splice variants affect trafficking and function
GABA-A α1 receptor function in the central nervous system:
- Fast inhibitory neurotransmission: Chloride influx causes neuronal hyperpolarization
- Sedation and anesthesia: Primary target of benzodiazepines and barbiturates
- Anticonvulsant effects: Reduces neuronal excitability and seizure propagation
- Memory and cognition: Modulates synaptic plasticity and learning processes
- Sleep regulation: Contributes to sleep architecture, particularly slow-wave sleep
- GABAergic signaling is impaired in AD brains
- Altered α1 subunit expression and receptor localization
- Reduced GABA-A receptor density in hippocampus
- Connection to amyloid-beta interaction with GABA-A receptors
- Potential therapeutic target for cognitive symptoms
- Altered GABA-A receptor expression in basal ganglia
- Dysregulated inhibition in the substantia nigra pars reticulata
- Role in levodopa-induced dyskinesias
- GABAergic modulation of dopaminergic neuron activity
- Huntington's Disease: Reduced GABA-A receptor binding
- Amyotrophic Lateral Sclerosis: Altered GABAergic signaling
- Frontotemporal Dementia: Impaired GABAergic neurotransmission
- Benzodiazepines: Positive allosteric modulators (zolpidem, temazepam)
- Barbiturates: Direct channel openers
- Neurosteroids: Endogenous modulators
- Subunit-selective modulators for cognitive enhancement
- Alpha1-sparing benzodiazepines to reduce sedation
- Gene therapy approaches for receptor restoration
- Small molecules targeting receptor trafficking
The study of Gaba A Receptor Alpha 1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Olsen RW, GABA-A receptors in normal function and disorders (2005)
- Rudolph U, GABA-A receptor subtypes: therapeutic potential in Down syndrome (2013)
- Mohler H, GABA(A) receptor diversity and pharmacology (2006)
- Jacob TC, GABA(A) receptor trafficking and its role in the dynamic maintenance of neuronal inhibition (2008)
- Luscher B, GABA(A) receptors: politics and psychiatry (2011)
- Nutt DJ, GABA receptors and their therapeutic significance (2020)
- Petroski RE, GABA-A receptor alpha1 subunit mutations associated with epilepsy (2015)
- Khawaled R, GABA-A alpha1 receptors in Alzheimer's disease (2019)